Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a

Liver International

Volumn 28, Issue 4, 2008, Pages 477-485

  Marcellin, Patrick ^a   Lau, George K K ^b   Zeuzem, Stefan ^c   Heathcote, E Jenny ^d   Pockros, Paul J ^e   Reddy, K Rajender ^f   Piratvisuth, Teerha ^g   Farci, Patrizia ^h   Chow, Wan Cheng ⁱ   Jia, Ji Dong ^j   Paik, Woon ^k   Wintfeld, Neil ^l   Pluck, Nigel ^m  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e SCRIPPS CLINIC   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^h Dipartimento di Scienze della Terra   (Italy)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j CAPITAL MEDICAL UNIVERSITY   (China)

^k Sungkyunkwan University School of Medicine   (South Korea)

^l HOFFMANN LA ROCHE INC   (United States)

^m ROCHE PRODUCTS LTD   (United Kingdom)

more..

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Health related quality of life; Hepatitis B virus; Hepatitis C virus; Pegylated interferon

Indexed keywords

HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; PLACEBO;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANTIGEN DETECTION; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYSTERIA; INCIDENCE; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RIGOR; SHORT FORM 36; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; THROMBOCYTOPENIA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 40949158076     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01696.x     Document Type: Article

References (30)

1. World Health Organization. Hepatitis B and C fact sheets. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 14/02/2006).
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
3. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-70.
4. Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 420-31.
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
6. Perry CM, Jarvis B. Peginterferon-alpha-2a (40kD): A review of its use in the management of chronic hepatitis C. Drugs 2001; 61: 2263-88.
7. Witthoeft T, Fuchs M. PEG-IFN alfa-2a plus ribavirin is superior compared to high dose consensus interferon (cIFN) and ribavirin in the treatment of patients with chronic hepatitis C. J Hepatol 2007; 46(Suppl. 1): S248.
8. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
9. Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: In patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-9.
10. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
11. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003; 10: 298-305.
12. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a alone, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2602-95.
13. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
14. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
15. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
16. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
18. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: A multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-305.
19. Li L, Wang HM, Shen Y. Chinese SF-36 health survey: Translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003; 57: 259-63.
20. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045-53.
21. van Zonneveld M, Flink HJ, Verhey E, et al. HBV 99-01 Study Group. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 1163-71.
22. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246-52.
23. Flink HJ, Sprengers D, Hansen BE, et al. HBV 99-01 Study Group. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alfa-2b therapy. Gut 2005; 54: 1604-9.
24. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: Effect of interferon treatment. Dig Dis 2002; 20: 284-8.
25. Kleinman A. Culture and depression. N Engl J Med 2004; 351: 951-3.
26. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-8.
27. Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 1154-63.
28. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-51.
29. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-8.
30. Trippler M, Erim Y, Bein S, Gerken G, Schlaak JF. Identification of candidate genes for IFN-mediated depression in HCV patients. J Hepatol 2007; 46(Suppl. 1): S244.